Department of Orthopaedic Surgery, University of Missouri, Columbia, Missouri.
Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, Missouri.
J Orthop Res. 2020 Apr;38(4):740-746. doi: 10.1002/jor.24508. Epub 2019 Nov 11.
This study characterizes outcomes associated with subchondroplasty (SCP) versus SCP enhanced with platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMC) treatment of impact-induced subchondral bone marrow lesions (BML) using a validated preclinical canine model. With IACUC approval, purpose-bred research hounds (n = 24) underwent arthroscopic impact injury (40 N) to both medial femoral condyles. At 3 months, functional assessments, arthroscopy, and magnetic resonance imaging (MRI) were performed. One knee in each dog (n = 24; n = 12 per endpoint) was randomly assigned to SCP with the other knee randomly assigned to SCP + PRP, SCP + BMC or sham injection (control) (n = 8 per group; n = 4 per endpoint). Dogs were evaluated at 6 and 12 months after treatment using functional assessments, radiography, arthroscopy, and MRI and humanely euthanatized at 6 or 12 months after treatment for histologic assessments. At 6 months post-treatment, comfortable range-of-motion (CROM) was higher (p < 0.04) in SCP + PRP and SCP + BMC knees compared with controls. At 1 year post-treatment, %Total Pressure Index was higher (p = 0.036) in SCP + BMC compared with controls, pain was lower (p < 0.05) in SCP + BMC and SCP + PRP compared with SCP and controls, and CROM was higher (p < 0.05) in SCP + BMC and SCP + PRP compared with SCP and controls. Knees treated with SCP + PRP and SCP + BMC had better (p < 0.05) MRI grades than SCP and controls. No statistically significant differences in arthroscopic or histologic pathology were noted. Clinical significance: Biologics added to SCP treatment may further enhance its beneficial effects by improving range-of-motion, pain severity, and limb loading through 1 year after treatment. However, these benefits must be considered alongside cost, logistics, and treatment availability. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:740-746, 2020.
本研究使用经过验证的临床前犬模型,描述了软骨下骨成形术(SCP)与 SCP 联合富血小板血浆(PRP)或骨髓抽吸浓缩物(BMC)治疗撞击诱导的软骨下骨骨髓病变(BML)的相关结果。经机构动物护理和使用委员会(IACUC)批准,目的饲养的研究猎犬(n=24)接受双侧股骨内侧髁关节镜撞击损伤(40N)。在 3 个月时,进行功能评估、关节镜检查和磁共振成像(MRI)。每只狗的一只膝关节(n=24;每个终点 n=12)随机分配 SCP,另一只膝关节随机分配 SCP+PRP、SCP+BMC 或假注射(对照)(每组 n=8;每个终点 n=4)。在治疗后 6 个月和 12 个月,使用功能评估、放射学、关节镜检查和 MRI 进行评估,并在治疗后 6 个月或 12 个月时对狗进行安乐死,以进行组织学评估。在治疗后 6 个月时,SCP+PRP 和 SCP+BMC 膝关节的舒适活动范围(CROM)更高(p<0.04)。在治疗后 1 年时,SCP+BMC 的总压力指数百分比(%Total Pressure Index)更高(p=0.036),SCP+BMC 和 SCP+PRP 的疼痛程度更低(p<0.05),SCP+BMC 和 SCP+PRP 的 CROM 更高(p<0.05),SCP 和对照组。SCP+PRP 和 SCP+BMC 治疗的膝关节的 MRI 分级优于 SCP 和对照组(p<0.05)。关节镜或组织病理学未见统计学差异。临床意义:生物制剂添加到 SCP 治疗中,可能会通过改善运动范围、疼痛严重程度和肢体负重,在治疗后 1 年内进一步增强其有益效果。然而,在考虑这些益处时,必须考虑成本、物流和治疗的可获得性。版权所有©2019 骨科研究协会。由 Wiley Periodicals, Inc. 出版。J Orthop Res 38:740-746, 2020.